Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
Authors Kyriazoglou A, Koutsoukos K, Zagouri F, Liontos M, Dimitriadis E, Tiniakos D, Dimopoulos MA
Received 25 June 2019
Accepted for publication 12 November 2019
Published 27 February 2020 Volume 2020:16 Pages 141—146
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Garry Walsh
Anastasios Kyriazoglou, 1 Konstantinos Koutsoukos, 1 Flora Zagouri, 1 Michalis Liontos, 1 Efthimios Dimitriadis, 2 Dina Tiniakos, 3, 4 Meletios Athanasios Dimopoulos 1
1Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece; 2Department of Genetics, Agios Savvas Hospital, Athens, Greece; 3Department of Pathology Aretaion Hospital, National & Kapodistrian University of Athens, Athens, Greece; 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Correspondence: Anastasios Kyriazoglou
Vasilisis Sofias 80, Athens 11528, Greece
Abstract: Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease (SD) as a response, after the completion of six cycles of this combination therapy.
Keywords: Olaratumab and Doxorubicin, metastatic hepatic epithelioid hemangioendothelioma, 1st line treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]